Herbert Eradat
Internal Medicine · Los Angeles, CANPI 1922143791
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $130,777 of the $186,358 with a category attached, or 70.2%. 21 manufacturers reported payments, led by AbbVie at 35.9% of the total. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $1285.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$67K
- Incyte Corporation$35K
- Beigene USA, Inc.$20K
- Genmab U.S., Inc.$13K
- Takeda Pharmaceuticals U.S.A., Inc.$13K
- Genentech USA, Inc.$7K
- plus $31K from 15 others
Across 453 payments — averaging $25,366 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$3.9M
- Genentech, Inc.$2.5M
- Bristol Myers Squibb$1.4M
- Genmab A/s$667K
- Acerta Pharma LLC$590K
- F. Hoffmann-la Roche AG$426K
- plus $1.9M from 16 others
What the payments were for
- Consulting fees$47,02325%
- Speaking & faculty fees$130,77770%
- Travel & lodging$2,0621%
- Food & beverage$6,4963%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $66,966 |
| Incyte Corporation | 21 | $34,856 |
| Beigene USA, Inc. | 17 | $20,365 |
| Genmab U.S., Inc. | 11 | $13,205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $12,698 |
| Genentech USA, Inc. | 14 | $7,193 |
| AstraZeneca | 6 | $6,460 |
| Genentech, Inc. | 3 | $4,434 |
| Morphosys, US Inc. | 2 | $3,888 |
| Beigene, Ltd. | 2 | $3,553 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $3,515 |
| Sanofi | 2 | $3,068 |
| Beone Medicines USA, Inc. | 3 | $2,658 |
| ADC Therapeutics America, Inc. | 4 | $1,876 |
| Epizyme, Inc. | 1 | $1,013 |
| Kyowa Kirin, Inc. | 3 | $231 |
| F. Hoffmann-la Roche AG | 2 | $170 |
| Philips North America LLC | 2 | $78 |
| Johnson & Johnson | 3 | $74 |
| Bristol Myers Squibb | 1 | $30 |
| Sobi, Inc | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$186,358 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 42 | $588,456 |
| VenclextaVenetoclax | 30 | $407,747 |
| CalquenceAcalabrutinib Maleate | 22 | $291,635 |
| Bexarotene | 18 | $274,313 |
| JakafiRuxolitinib Phosphate | 11 | $168,324 |
| ProcritEpoetin Alfa | 12 | $31,640 |
| Acyclovir | 24 | $682 |
| Prednisone | 22 | $308 |
| MethotrexateMethotrexate Sodium | 14 | $251 |
| Ciprofloxacin Hcl | 13 | $65 |
| Montelukast Sodium | 11 | $53 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $52 |
| Omeprazole | 14 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $20,365 | $588,45642 claims |
| AbbVieVenclexta | $66,966 | $407,74730 claims |
| AstraZenecaCalquence | $6,460 | $291,63522 claims |
| Incyte CorporationJakafi | $34,856 | $168,32411 claims |
| Johnson & JohnsonProcrit | $74 | $31,64012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William HardyLos Angeles$704K
- Soha DolatabadiLos Angeles$458K
- Matthew HerrmannLos Angeles$384K
- Koppany VisnyeiLos Angeles$287K
- Jaime BetancourtLos Angeles$286K
- William KingLos Angeles$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.